NASDAQ: MLTX
Moonlake Immunotherapeutics Stock

$39.84+1.45 (+3.78%)
Updated Mar 27, 2025
MLTX Price
$39.84
Fair Value Price
$2.82
Market Cap
$2.55B
52 Week Low
$36.52
52 Week High
$58.26
P/E
-21.08x
P/B
5.71x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$121.24M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$117M
Beta
0.56
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A

MLTX Overview

MoonLake Immunotherapeutics develops medicines for immunologic diseases, including inflammatory skin and joint diseases. It focuses on enhancing its novel tri-specific Nanobody Sonelokimab (SLK) product, an inhibitor to treat multiple inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F. The company is conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine MLTX's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -9.02% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
MLTX
Ranked
#472 of 477

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important MLTX news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MLTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MLTX ($39.84) is overvalued by 1,310.36% relative to our estimate of its Fair Value price of $2.82 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MLTX ($39.84) is not significantly undervalued (1,310.36%) relative to our estimate of its Fair Value price of $2.82 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MLTX due diligence checks available for Premium users.

Valuation

MLTX fair value

Fair Value of MLTX stock based on Discounted Cash Flow (DCF)

Price
$39.84
Fair Value
$2.82
Overvalued by
1,310.36%
MLTX ($39.84) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MLTX ($39.84) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MLTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MLTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-21.08x
Industry
-123.64x
Market
31.08x

MLTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
5.71x
Industry
4.52x
MLTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MLTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$46.4M
Profit Margin
0%
MLTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$477.9M
Liabilities
$24.5M
Debt to equity
0.06
MLTX's short-term assets ($474.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MLTX's short-term assets ($474.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MLTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$48.5M
Investing
-$147.3M
Financing
$150.7k
MLTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MLTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
MLTXF$2.55B+3.78%-21.08x5.71x
FOLDB$2.58B+0.82%-47.72x13.29x
XENED$2.64B-0.92%-11.45x3.49x
NAMSC$2.46B-0.66%-8.32x3.09x
VCYTC$2.42B+0.16%97.19x2.06x

Moonlake Immunotherapeutics Stock FAQ

What is Moonlake Immunotherapeutics's quote symbol?

(NASDAQ: MLTX) Moonlake Immunotherapeutics trades on the NASDAQ under the ticker symbol MLTX. Moonlake Immunotherapeutics stock quotes can also be displayed as NASDAQ: MLTX.

If you're new to stock investing, here's how to buy Moonlake Immunotherapeutics stock.

What is the 52 week high and low for Moonlake Immunotherapeutics (NASDAQ: MLTX)?

(NASDAQ: MLTX) Moonlake Immunotherapeutics's 52-week high was $58.26, and its 52-week low was $36.52. It is currently -31.62% from its 52-week high and 9.09% from its 52-week low.

How much is Moonlake Immunotherapeutics stock worth today?

(NASDAQ: MLTX) Moonlake Immunotherapeutics currently has 64,012,047 outstanding shares. With Moonlake Immunotherapeutics stock trading at $39.84 per share, the total value of Moonlake Immunotherapeutics stock (market capitalization) is $2.55B.

Moonlake Immunotherapeutics stock was originally listed at a price of $10.49 in Oct 20, 2020. If you had invested in Moonlake Immunotherapeutics stock at $10.49, your return over the last 4 years would have been 279.79%, for an annualized return of 39.6% (not including any dividends or dividend reinvestments).

How much is Moonlake Immunotherapeutics's stock price per share?

(NASDAQ: MLTX) Moonlake Immunotherapeutics stock price per share is $39.84 today (as of Mar 27, 2025).

What is Moonlake Immunotherapeutics's Market Cap?

(NASDAQ: MLTX) Moonlake Immunotherapeutics's market cap is $2.55B, as of Mar 28, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Moonlake Immunotherapeutics's market cap is calculated by multiplying MLTX's current stock price of $39.84 by MLTX's total outstanding shares of 64,012,047.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.